Mochida and Fuji submit biosimilar G-CSF in Japan

December 27, 2011 11:08 AM

Mochida Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. filed the first biosimilar G-CSF in Japan.

According to Fuji Pharma’s press release, the development of the product was started in February 2010 when Mochida made the joint development agreement with Gene Technology Co.

FKS0808 will be the first biosimilar G-CSF to be marketed in Japan and it will be marketed by a co-marketing strategy which means 2 brands and 2 channels.

Mochida’s interest in biosimilars were known before as they had signed an license and collaboration agreement with Gedeon Richter of Hungary last year. With that agreement, Mochida is obliged to make payments related to the fulfilment of certain regulatory criteria together with contributions to development costs while Richter is responsible for the global development of the biosimilar product line.

If you are interested in Japanese biosimilars market, following posts might be helpful for you:
Japanese Biosimilars Guideline
Japanese Biosimilars Market

 

Sources: 
1- Fuji Pharma press release
2- http://www.richter.hu/EN/Pages/pr101214a.aspx

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!